维持性血液透析合并肌少症患者临床治疗及营养干预现状  

Current status of clinical treatment and nutritional intervention in maintenance hemodialysis patients with sarcopenia

作　　者：游睿 曹正江 汤曦 周莉 You Rui;Cao Zhengjiang;Tang Xi;Zhou Li(Hemodialysis Room,Department of Nephrology,West China Hospital,Sichuan University/West China School of Nursing,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院肾脏内科血透室/四川大学华西护理学院,成都610041

出　　处：《中国医药》2024年第7期1113-1116,共4页China Medicine

基　　金：四川省自然科学基金(2023NSFSC0604);四川大学研究生教育教学改革研究项目(GSSCU2021136)。

摘　　要：肌少症是维持性血液透析(MHD)患者的常见并发症,对患者的活动能力及生活质量产生严重不利影响,并与MHD患者的不良预后密切相关。因此,早期诊断和干预肌少症对MHD患者具有重要临床意义。对有肌少症高危因素的MHD患者要重视危险因素的控制,降低暴露水平,预防疾病发生或发展。肌少症目前主要的治疗及干预策略包括药物治疗、运动以及营养干预。为增加对MHD肌少症的认知与提高防治水平,现针对MHD肌少症的患病情况、危险因素、治疗及干预现状进行综述。Sarcopenia is a common complication in maintenance hemodialysis(MHD)patients,which has a serious adverse impact on patients′mobility and quality of life,and is closely related to the poor prognosis of MHD patients.Therefore,early diagnosis and intervention of sarcopenia are of great clinical significance for MHD patients.MHD patients with high risk factors of sarcopenia should pay attention to the control of risk factors,reduce the exposure level,and prevent the occurrence or development of the disease.At present,the main treatment and intervention strategies for sarcopenia include drug therapy,exercise and nutritional intervention.In order to increase the awareness and improve the prevention and treatment level of MHD sarcopenia,this article reviews the prevalence,risk factors,treatment and intervention status of MHD sarcopenia.

关 键 词：维持性血液透析 肌少症 干预 综述 

分 类 号：R459.5[医药卫生—治疗学]